Peter Palese

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2556190/publications.pdf

Version: 2024-02-01

341
papers

46,654
citations

1094

112
h-index

2233

201
g-index

362
all docs

362
docs citations

362
times ranked

26765
citing authors

#	ARTICLE	IF	CITATIONS
1	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy, 2022, 30, 2024-2047.	3.7	14
2	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391.	15.2	65
3	Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature, 2022, 602, 314-320.	13.7	78
4	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine, 2022, 45, 101323.	3.2	26
5	Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1â€“2 randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 1062-1075.	4.6	10
6	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine, 2022, 40, 3621-3632.	1.7	15
7	Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
8	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiology Spectrum, 2022, 10, .	1.2	14
9	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	15.2	204
10	Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines, 2021, 9, 40.	2.1	14
11	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
12	An Egg-Derived Sulfated<i>N</i>-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. MBio, 2021, 12, e0083821.	1.8	8
13	First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Science Translational Medicine, 2021, 13, .	5.8	38
14	Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting. Viruses, 2021, 13, 1909.	1.5	2
15	Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Molecular Therapy - Methods and Clinical Development, 2021, 22, 84-95.	1.8	20
16	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio, 2021, 12, e0190821.	1.8	32
17	Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Frontiers in Immunology, 2021, 12, 746447.	2.2	9
18	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 2021, 12, 6197.	5.8	61

#	ARTICLE	IF	CITATIONS
19	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Scientific Reports, 2021, 11, 22164.	1.6	7
20	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Frontiers in Immunology, 2021, 12, 791764.	2.2	14
21	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	4.6	103
22	Is a Universal Influenza Virus Vaccine Possible?. Annual Review of Medicine, 2020, 71, 315-327.	5.0	84
23	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Journal of Virology, 2020, 94, .	1.5	54
24	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	2.7	77
25	The Long Road to a Universal Influenza Virus Vaccine. Proceedings (mdpi), 2020, 50, .	0.2	0
26	A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro. Proceedings (mdpi), 2020, 50, .	0.2	0
27	Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity, 2020, 53, 1230-1244.e5.	6.6	61
28	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	2.1	61
29	Current Challenges in Vaccinology. Frontiers in Immunology, 2020, 11, 1181.	2.2	47
30	A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Molecular Therapy, 2020, 28, 1569-1584.	3.7	188
31	Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. Journal of Virology, 2020, 94, .	1.5	19
32	A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Scientific Reports, 2020, 10, 9750.	1.6	4
33	Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet, The, 2020, 395, e42-e43.	6.3	182
34	High-complexity extracellular barcoding using a viral hemagglutinin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2767-2769.	3.3	2
35	H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model. MBio, 2020, 11, .	1.8	11
36	Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. Journal of Virology, 2019, 93, .	1.5	18

#	ARTICLE	IF	CITATIONS
37	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. Npj Vaccines, 2019, 4, 31.	2.9	40
38	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine, 2019, 49, 96-105.	2.7	47
39	An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines, 2019, 7, 117.	2.1	12
40	Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain. Journal of Infectious Diseases, 2019, 219, S62-S67.	1.9	72
41	Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein. Journal of Virology, 2019, 93, .	1.5	12
42	Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. MBio, 2019, 10, .	1.8	57
43	Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Frontiers in Immunology, 2019, 10, 756.	2.2	48
44	Development of Influenza B Universal Vaccine Candidates Using the â€œMosaicâ€•Hemagglutinin Approach. Journal of Virology, 2019, 93, .	1.5	53
45	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. Npj Vaccines, 2019, 4, 51.	2.9	18
46	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. Journal of Virology, 2019, 93, .	1.5	21
47	Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice. ImmunoHorizons, 2019, 3, 133-148.	0.8	33
48	Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Current Opinion in Immunology, 2018, 53, 51-57.	2.4	32
49	A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model. Cell Reports, 2018, 22, 1-7.	2.9	42
50	Is It Possible to Develop a â€œUniversalâ€•Influenza Virus Vaccine?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028845.	2.3	75
51	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation, 2018, 128, 4992-4996.	3.9	51
52	Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications, 2018, 9, 4560.	5.8	88
53	Influenza. Nature Reviews Disease Primers, 2018, 4, 3.	18.1	880
54	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Journal of Virology, 2018, 92, .	1.5	24

#	ARTICLE	IF	CITATIONS
55	Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host and Microbe, 2018, 24, 18-24.	5.1	73
56	An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS ONE, 2018, 13, e0194830.	1.1	27
57	The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. Journal of Virology, 2018, 92, .	1.5	18
58	Influenza Viruses: High Rate of Mutation and Evolution. , 2018, , 123-135.		3
59	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110
60	Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nature Immunology, 2017, 18, 464-473.	7.0	131
61	Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion. Journal of Virology, 2017, 91, .	1.5	30
62	Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. MBio, 2017, 8, .	1.8	112
63	Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. Journal of Virology, 2017, 91, .	1.5	70
64	Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses. Antiviral Research, 2017, 142, 12-15.	1.9	6
65	Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nature Communications, 2017, 8, 846.	5.8	134
66	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10172-10177.	3.3	42
67	Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for <i>In Vivo</i> Protection in a Serum Transfer Mouse Challenge Model. MBio, 2017, 8, .	1.8	66
68	A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. Npj Vaccines, 2017, 2, 26.	2.9	113
69	Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nature Microbiology, 2017, 2, 1415-1424.	5.9	96
70	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Journal of Virology, 2017, 91, .	1.5	32
71	A broadly protective antibody. Nature, 2017, 551, 310-311.	13.7	1
72	Influenza Virus. , 2016, , 1009-1058.		5

#	ARTICLE	IF	CITATIONS
73	A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. Npj Vaccines, 2016, 1, .	2.9	65
74	Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio, 2016, 7, e00257.	1.8	26
75	Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11931-11936.	3.3	153
76	Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio, 2016, 7, .	1.8	100
77	Profile of Charles M. Rice, Ralf F. W. Bartenschlager, and Michael J. Sofia, 2016 Laskerâ€“DeBakey Clinical Medical Research Awardees. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13934-13937.	3.3	3
78	Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5944-E5951.	3.3	108
79	Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host and Microbe, 2016, 19, 800-813.	5.1	238
80	Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity, 2016, 44, 46-58.	6.6	110
81	Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. Journal of Virology, 2016, 90, 3789-3793.	1.5	42
82	Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. Journal of Virology, 2016, 90, 2544-2550.	1.5	36
83	Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3861-3866.	3.3	44
84	Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio, 2016, 7, e01996-15.	1.8	116
85	Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. Journal of Virology, 2016, 90, 3268-3273.	1.5	69
86	Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. Journal of Clinical Investigation, 2016, 126, 605-610.	3.9	349
87	Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies. Antimicrobial Agents and Chemotherapy, 2015, 59, 4162-4172.	1.4	58
88	Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins. Cell Reports, 2015, 11, 1331-1338.	2.9	64
89	Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice. MBio, 2015, 6, e02556.	1.8	173
90	Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies. Journal of Virology, 2015, 89, 12226-12231.	1.5	17

#	ARTICLE	IF	CITATIONS
91	A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein. ACS Infectious Diseases, 2015, 1, 98-109.	1.8	22
92	The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA. Journal of Virology, 2015, 89, 2241-2252.	1.5	56
93	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. Journal of Virology, 2015, 89, 3221-3235.	1.5	92
94	Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones. Journal of Virology, 2015, 89, 3610-3618.	1.5	80
95	Advances in the development of influenza virus vaccines. Nature Reviews Drug Discovery, 2015, 14, 167-182.	21.5	496
96	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell, 2015, 162, 160-169.	13.5	171
97	Immune history profoundly affects broadly protective B cell responses to influenza. Science Translational Medicine, 2015, 7, 316ra192.	5.8	353
98	In memoriam â€" Richard M. Elliott (1954â€"2015). Journal of General Virology, 2015, 96, 1975-1978.	1.3	4
99	Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. Journal of Clinical Investigation, 2015, 125, 1255-1268.	3.9	115
100	High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS ONE, 2015, 10, e0125618.	1.1	35
101	Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge. Journal of Virology, 2014, 88, 3976-3985.	1.5	52
102	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	5.8	590
103	Peering into the Crystal Ball: Influenza Pandemics and Vaccine Efficacy. Cell, 2014, 157, 294-299.	13.5	26
104	H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge. Journal of Virology, 2014, 88, 2340-2343.	1.5	102
105	Universal influenza virus vaccines: need for clinical trials. Nature Immunology, 2014, 15, 3-5.	7.0	66
106	Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain. Journal of Virology, 2014, 88, 699-704.	1.5	148
107	Broadly neutralizing hemagglutinin stalkâ€"specific antibodies require FcÎ³R interactions for protection against influenza virus in vivo. Nature Medicine, 2014, 20, 143-151.	15.2	680
108	Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. Journal of Virology, 2014, 88, 13580-13592.	1.5	110

#	ARTICLE	IF	CITATIONS
109	Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans. Journal of Virology, 2014, 88, 13260-13268.	1.5	136
110	Long-term survival of influenza virus infected club cells drives immunopathology. Journal of Experimental Medicine, 2014, 211, 1707-1714.	4.2	74
111	Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets. Journal of Virology, 2014, 88, 3432-3442.	1.5	128
112	Advances in Universal Influenza Virus Vaccine Design and Antibody Mediated Therapies Based on Conserved Regions of the Hemagglutinin. Current Topics in Microbiology and Immunology, 2014, 386, 301-321.	0.7	115
113	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	3.3	197
114	Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.. Journal of Clinical Oncology, 2014, 32, 3051-3051.	0.8	1
115	A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Antiviral Research, 2013, 100, 29-37.	1.9	12
116	Influenza virus hemagglutinin stalk-based antibodies and vaccines. Current Opinion in Virology, 2013, 3, 521-530.	2.6	286
117	Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20248-20253.	3.3	159
118	Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System. Journal of Visualized Experiments, 2013, , e51112.	0.2	132
119	Toward a Universal Influenza Virus Vaccine: Prospects and Challenges. Annual Review of Medicine, 2013, 64, 189-202.	5.0	270
120	H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice. Journal of Virology, 2013, 87, 4728-4737.	1.5	138
121	Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521.	6.0	34
122	Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies. Journal of Virology, 2013, 87, 6542-6550.	1.5	360
123	<i>In Vivo</i> Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies. Journal of Virology, 2013, 87, 8272-8281.	1.5	133
124	Colocalization of Different Influenza Viral RNA Segments in the Cytoplasm before Viral Budding as Shown by Single-molecule Sensitivity FISH Analysis. PLoS Pathogens, 2013, 9, e1003358.	2.1	142
125	Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs. Journal of Virology, 2013, 87, 7793-7804.	1.5	73
126	Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nature Communications, 2013, 4, 2854.	5.8	146

#	ARTICLE	IF	CITATIONS
127	Serum- and Glucocorticoid-Regulated Kinase 1 Is Required for Nuclear Export of the Ribonucleoprotein of Influenza A Virus. Journal of Virology, 2013, 87, 6020-6026.	1.5	20
128	A Sendai Virus-Derived RNA Agonist of RIG-I as a Virus Vaccine Adjuvant. Journal of Virology, 2013, 87, 1290-1300.	1.5	107
129	Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis. Science Translational Medicine, 2013, 5, 198ra107.	5.8	157
130	Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin. Journal of Virology, 2013, 87, 8235-8240.	1.5	48
131	1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans. Journal of Infectious Diseases, 2013, 207, 98-105.	1.9	77
132	Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies. PLoS ONE, 2013, 8, e79194.	1.1	58
133	Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance. Journal of Virology, 2012, 86, 5386-5389.	1.5	33
134	A Novel Small Molecule Inhibitor of Influenza A Viruses that Targets Polymerase Function and Indirectly Induces Interferon. PLoS Pathogens, 2012, 8, e1002668.	2.1	42
135	Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis. Science, 2012, 335, 1463-1463.	6.0	108
136	Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401.	6.0	58
137	H5N1 influenza viruses: Facts, not fear. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2211-2213.	3.3	61
138	Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2573-2578.	3.3	244
139	Response to Comment on â€œSeroevidence for H5N1 Influenza Infections in Humans: Meta-Analysisâ€. Science, 2012, 336, 1506-1506.	6.0	4
140	Attenuated Influenza Virus Construct with Enhanced Hemagglutinin Protein Expression. Journal of Virology, 2012, 86, 5782-5790.	1.5	16
141	Transmission of Influenza B Viruses in the Guinea Pig. Journal of Virology, 2012, 86, 4279-4287.	1.5	72
142	Don't censor life-saving science. Nature, 2012, 481, 115-115.	13.7	29
143	NS1-Truncated Live Attenuated Virus Vaccine Provides Robust Protection to Aged Mice from Viral Challenge. Journal of Virology, 2012, 86, 10293-10301.	1.5	53
144	Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 2012, 7, 347-367.	1.0	185

#	ARTICLE	IF	CITATIONS
145	Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes. Journal of Virology, 2012, 86, 5774-5781.	1.5	241
146	A Majority of Infectious Newcastle Disease Virus Particles Contain a Single Genome, while a Minority Contain Multiple Genomes. Journal of Virology, 2012, 86, 10852-10856.	1.5	20
147	Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature, 2012, 489, 526-532.	13.7	434
148	A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates. PLoS ONE, 2012, 7, e43603.	1.1	146
149	Identification of Small Molecules with Type I Interferon Inducing Properties by High-Throughput Screening. PLoS ONE, 2012, 7, e49049.	1.1	27
150	Influenza Virus Infection in Guinea Pigs Raised as Livestock, Ecuador. Emerging Infectious Diseases, 2012, 18, 1135-1138.	2.0	15
151	Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. Journal of Virology, 2012, 86, 10302-10307.	1.5	93
152	The Influenza A Virus PB2, PA, NP, and M Segments Play a Pivotal Role during Genome Packaging. Journal of Virology, 2012, 86, 7043-7051.	1.5	72
153	One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9101-9106.	3.3	150
154	Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon by Binding to MAVS and Decreasing Mitochondrial Membrane Potential. Journal of Virology, 2012, 86, 8359-8366.	1.5	162
155	A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy<i>In Vivo</i>. Journal of Virology, 2012, 86, 6179-6188.	1.5	150
156	Live Attenuated Influenza Virus Vaccines: NS1 Truncation as an Approach to Virus Attenuation. , 2011, , 195-221.		0
157	Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. Journal of Virology, 2011, 85, 6015-6023.	1.5	119
158	Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head and Neck, 2011, 33, 1394-1399.	0.9	33
159	Transmission of a 2009 Pandemic Influenza Virus Shows a Sensitivity to Temperature and Humidity Similar to That of an H3N2 Seasonal Strain. Journal of Virology, 2011, 85, 1400-1402.	1.5	123
160	The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model. Journal of Virology, 2011, 85, 11235-11241.	1.5	127
161	Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice. Journal of Virology, 2011, 85, 2235-2246.	1.5	42
162	Budding Capability of the Influenza Virus Neuraminidase Can Be Modulated by Tetherin. Journal of Virology, 2011, 85, 2480-2491.	1.5	83

#	ARTICLE	IF	CITATIONS
163	The influenza A virus protein PB1-F2. Virulence, 2011, 2, 542-546.	1.8	29
164	The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses. Journal of Virology, 2011, 85, 12825-12829.	1.5	82
165	A Reassortment-Incompetent Live Attenuated Influenza Virus Vaccine for Protection against Pandemic Virus Strains. Journal of Virology, 2011, 85, 6832-6843.	1.5	43
166	Catching a Moving Target. Science, 2011, 333, 834-835.	6.0	24
167	Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5777-5782.	3.3	213
168	A Single N66S Mutation in the PB1-F2 Protein of Influenza A Virus Increases Virulence by Inhibiting the Early Interferon Response <i>In Vivo</i>. Journal of Virology, 2011, 85, 652-662.	1.5	135
169	Why Do Influenza Virus Subtypes Die Out? A Hypothesis. MBio, 2011, 2, .	1.8	103
170	The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein. PLoS Pathogens, 2011, 7, e1002067.	2.1	206
171	Influenza Virus: The Biology of a Changing Virus. , 2011, , 3-26.		2
172	Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus. Journal of Gastrointestinal Surgery, 2010, 14, 7-14.	0.9	11
173	Human host factors required for influenza virus replication. Nature, 2010, 463, 813-817.	13.7	755
174	PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models. Journal of Virology, 2010, 84, 4442-4450.	1.5	134
175	Transmission of Pandemic H1N1 Influenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment. Journal of Virology, 2010, 84, 21-26.	1.5	118
176	Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins. PLoS Pathogens, 2010, 6, e1000796.	2.1	251
177	Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain. MBio, 2010, 1, .	1.8	460
178	Hemagglutinin-Pseudotyped Green Fluorescent Protein-Expressing Influenza Viruses for the Detection of Influenza Virus Neutralizing Antibodies. Journal of Virology, 2010, 84, 2157-2163.	1.5	94
179	A Nine-Segment Influenza A Virus Carrying Subtype H1 and H3 Hemagglutinins. Journal of Virology, 2010, 84, 8062-8071.	1.5	29
180	Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models. Journal of Virology, 2010, 84, 11219-11226.	1.5	94

#	Article	IF	Citations
181	Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines. PLoS Pathogens, 2010, 6, e1000745.	2.1	166
182	Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nature Communications, 2010, 1, 28.	5.8	52
183	Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries. PLoS Pathogens, 2010, 6, e1000990.	2.1	63
184	Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18979-18984.	3.3	273
185	Rewiring the RNAs of influenza virus to prevent reassortment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15891-15896.	3.3	72
186	Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model. Journal of Virology, 2009, 83, 2803-2818.	1.5	79
187	Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza. Journal of Virology, 2009, 83, 1742-1753.	1.5	217
188	Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses. Molecular Therapy, 2009, 17, 697-706.	3.7	84
189	Transmission of Influenza Virus in a Mammalian Host Is Increased by PB2 Amino Acids 627K or 627E/701N. PLoS Pathogens, 2009, 5, e1000252.	2.1	497
190	Transmission of Influenza Virus via Aerosols and Fomites in the Guinea Pig Model. Journal of Infectious Diseases, 2009, 199, 858-865.	1.9	179
191	Nipah Virus Edits Its P Gene at High Frequency To Express the V and W Proteins. Journal of Virology, 2009, 83, 3982-3987.	1.5	72
192	Universal epitopes of influenza virus hemagglutinins?. Nature Structural and Molecular Biology, 2009, 16, 233-234.	3.6	47
193	Influenza A viruses with truncated NS1 as modified live virus vaccines: Pilot studies of safety and efficacy in horses. Equine Veterinary Journal, 2009, 41, 87-92.	0.9	52
194	Unraveling the Mystery of Swine Influenza Virus. Cell, 2009, 137, 983-985.	13.5	97
195	Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine, 2009, 27, 3766-3774.	1.7	73
196	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
197	Recombinant Vectors as Influenza Vaccines. Current Topics in Microbiology and Immunology, 2009, 333, 243-267.	0.7	17
198	Transmission of influenza virus in temperate zones is predominantly by aerosol, in the tropics by contactA hypothesis. PLOS Currents, 2009, 1, RRN1002.	1.4	77

#	ARTICLE	IF	CITATIONS
199	Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Research, 2008, 80, 124-134.	1.9	81
200	A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine, 2008, 26, 522-531.	1.7	51
201	The biology of influenza viruses. Vaccine, 2008, 26, D49-D53.	1.7	802
202	Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5986-5991.	3.3	248
203	Highly Conserved Regions of Influenza A Virus Polymerase Gene Segments Are Critical for Efficient Viral RNA Packaging. Journal of Virology, 2008, 82, 2295-2304.	1.5	144
204	Influenza B Virus NS1-Truncated Mutants: Live-Attenuated Vaccine Approach. Journal of Virology, 2008, 82, 10580-10590.	1.5	102
205	A Seven-Segmented Influenza A Virus Expressing the Influenza C Virus Glycoprotein HEF. Journal of Virology, 2008, 82, 6419-6426.	1.5	34
206	Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3064-3069.	3.3	140
207	Cellular Proteins in Influenza Virus Particles. PLoS Pathogens, 2008, 4, e1000085.	2.1	268
208	Human Genes and Influenza. Journal of Infectious Diseases, 2008, 197, 1-3.	1.9	26
209	High Temperature (30Â°C) Blocks Aerosol but Not Contact Transmission of Influenza Virus. Journal of Virology, 2008, 82, 5650-5652.	1.5	292
210	Expression of Transgenes from Newcastle Disease Virus with a Segmented Genome. Journal of Virology, 2008, 82, 2692-2698.	1.5	29
211	Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol. Journal of Virology, 2008, 82, 10052-10058.	1.5	90
212	The 1918 Influenza Pandemic: Lessons from the Past Raise Questions for the Future. Monographs in Virology, 2008, , 272-286.	0.6	5
213	Influenza virus: The biology of a changing virus. , 2008, , 9-30.		1
214	Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists. Journal of Virology, 2007, 81, 548-557.	1.5	601
215	Specific Residues of the Influenza A Virus Hemagglutinin Viral RNA Are Important for Efficient Packaging into Budding Virions. Journal of Virology, 2007, 81, 9727-9736.	1.5	188
216	A Single Mutation in the PB1-F2 of H5N1 (HK/97) and 1918 Influenza A Viruses Contributes to Increased Virulence. PLoS Pathogens, 2007, 3, e141.	2.1	427

#	Article	IF	Citations
217	Influenza Virus Transmission Is Dependent on Relative Humidity and Temperature. PLoS Pathogens, 2007, 3, e151.	2.1	1,259
218	Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. Journal of Virology, 2007, 81, 9812-9824.	1.5	472
219	Influenza Virus Transmission: Basic Science and Implications for the Use of Antiviral Drugs During a Pandemic. Infectious Disorders - Drug Targets, 2007, 7, 318-328.	0.4	52
220	Effective replication of human influenza viruses in mice lacking a major Î±2,6 sialyltransferase. Virus Research, 2007, 126, 9-18.	1.1	59
221	Influenza A Virus PB1-F2: A Small Protein with a Big Punch. Cell Host and Microbe, 2007, 2, 207-209.	5.1	72
222	A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission. Science, 2007, 315, 655-659.	6.0	508
223	Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nature Immunology, 2007, 8, 1188-1193.	7.0	189
224	Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. Influenza and Other Respiratory Viruses, 2007, 1, 95-104.	1.5	9
225	Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology, 2007, 122, 28-37.	2.0	54
226	Influenza pandemics: past and future. Retrovirology, 2006, 3, 1.	0.9	0
227	Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8203-8208.	3.3	207
228	Glycan Microarray Analysis of the Hemagglutinins from Modern and Pandemic Influenza Viruses Reveals Different Receptor Specificities. Journal of Molecular Biology, 2006, 355, 1143-1155.	2.0	570
229	What Can We Learn from Reconstructing the Extinct 1918 Pandemic Influenza Virus?. Immunity, 2006, 24, 121-124.	6.6	46
230	Making Better Influenza Virus Vaccines?. Emerging Infectious Diseases, 2006, 12, 61-65.	2.0	135
231	Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature, 2006, 443, 578-581.	13.7	515
232	Sequence analysis and receptor specificity of the hemagglutinin of a recent influenza H2N2 virus isolated from chicken in North America. Glycoconjugate Journal, 2006, 23, 93-99.	1.4	19
233	Influenza A Virus PB1-F2 Protein Contributes to Viral Pathogenesis in Mice. Journal of Virology, 2006, 80, 7976-7983.	1.5	276
234	7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase. Journal of Virology, 2006, 80, 785-793.	1.5	142

#	ARTICLE	IF	CITATIONS
235	The guinea pig as a transmission model for human influenza viruses. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9988-9992.	3.3	317
236	An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein. Traffic, 2005, 6, 205-213.	1.3	127
237	Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1. PLoS Pathogens, 2005, 1, e4.	2.1	306
238	Nuclear Localization of the Nipah Virus W Protein Allows for Inhibition of both Virus- and Toll-Like Receptor 3-Triggered Signaling Pathways. Journal of Virology, 2005, 79, 6078-6088.	1.5	174
239	Pathogenicity of Influenza Viruses with Genes from the 1918 Pandemic Virus: Functional Roles of Alveolar Macrophages and Neutrophils in Limiting Virus Replication and Mortality in Mice. Journal of Virology, 2005, 79, 14933-14944.	1.5	466
240	Attenuation of Equine Influenza Viruses through Truncations of the NS1 Protein. Journal of Virology, 2005, 79, 8431-8439.	1.5	220
241	A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity. Journal of Virology, 2005, 79, 11533-11536.	1.5	356
242	Viruses and the Innate Immune System. , 2005, , 1-18.		0
243	Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus. Science, 2005, 310, 77-80.	6.0	1,158
244	Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1350-1355.	3.3	378
245	Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively. Journal of Virology, 2004, 78, 5633-5641.	1.5	206
246	Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors. Journal of Virology, 2004, 78, 9366-9375.	1.5	37
247	Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3166-3171.	3.3	171
248	Influenza: old and new threats. Nature Medicine, 2004, 10, S82-S87.	15.2	502
249	Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus. Science, 2004, 303, 1866-1870.	6.0	440
250	Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Research, 2003, 95, 3-12.	1.1	114
251	The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3. Journal of Virology, 2003, 77, 7945-7956.	1.5	432
252	Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction. Journal of Virology, 2003, 77, 9522-9532.	1.5	208

#	ARTICLE	IF	CITATIONS
253	Chimeric Influenza A Viruses with a Functional Influenza B Virus Neuraminidase or Hemagglutinin. Journal of Virology, 2003, 77, 9116-9123.	1.5	32
254	Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8 + -T-Cell Epitope Derived from the Circumsporozoite Protein of Plasmodium yoelii. Journal of Virology, 2003, 77, 11859-11866.	1.5	38
255	Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene. Journal of Virology, 2003, 77, 7411-7424.	1.5	28
256	Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins. Journal of Virology, 2003, 77, 1501-1511.	1.5	348
257	Apical Budding of a Recombinant Influenza A Virus Expressing a Hemagglutinin Protein with a Basolateral Localization Signal. Journal of Virology, 2002, 76, 3544-3553.	1.5	49
258	Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10736-10741.	3.3	339
259	Functional Replacement of the Carboxy-Terminal Two-Thirds of the Influenza A Virus NS1 Protein with Short Heterologous Dimerization Domains. Journal of Virology, 2002, 76, 12951-12962.	1.5	94
260	Effects of Influenza A Virus NS1 Protein on Protein Expression: the NS1 Protein Enhances Translation and Is Not Required for Shutoff of Host Protein Synthesis. Journal of Virology, 2002, 76, 1206-1212.	1.5	105
261	Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13849-13854.	3.3	127
262	The makings of a killer. Nature Medicine, 2002, 8, 927-928.	15.2	7
263	Influenza vaccines: present and future. Journal of Clinical Investigation, 2002, 110, 9-13.	3.9	90
264	Series Introduction: New directions in vaccine research. Journal of Clinical Investigation, 2002, 109, 1517-1518.	3.9	2
265	Influenza vaccines: present and future. Journal of Clinical Investigation, 2002, 110, 9-13.	3.9	68
266	Recombinant Newcastle Disease Virus as a Vaccine Vector. Journal of Virology, 2001, 75, 11868-11873.	1.5	220
267	Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2746-2751.	3.3	266
268	A novel influenza A virus mitochondrial protein that induces cell death. Nature Medicine, 2001, 7, 1306-1312.	15.2	901
269	Influenza B and C Virus NEP (NS2) Proteins Possess Nuclear Export Activities. Journal of Virology, 2001, 75, 7375-7383.	1.5	61
270	Cellular Splicing Factor RAF-2p48/NPI-5/BAT1/UAP56 Interacts with the Influenza Virus Nucleoprotein and Enhances Viral RNA Synthesis. Journal of Virology, 2001, 75, 1899-1908.	1.5	154

#	ARTICLE	IF	CITATIONS
271	Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4309-4314.	3.3	288
272	Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication. Journal of Virology, 2000, 74, 6203-6206.	1.5	328
273	Influenza A Virus NS1 Protein Prevents Activation of NF-ÎºB and Induction of Alpha/Beta Interferon. Journal of Virology, 2000, 74, 11566-11573.	1.5	505
274	Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza A Virus NS1 Protein. Journal of Virology, 2000, 74, 7989-7996.	1.5	533
275	The Ebola virus VP35 protein functions as a type I IFN antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12289-12294.	3.3	442
276	Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. Journal of General Virology, 2000, 81, 737-742.	1.3	21
277	Rescue of Influenza A Virus from Recombinant DNA. Journal of Virology, 1999, 73, 9679-9682.	1.5	741
278	Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine, 1999, 17, 887-892.	1.7	45
279	Mutation of Neuraminidase Cysteine Residues Yields Temperature-Sensitive Influenza Viruses. Journal of Virology, 1999, 73, 8095-8103.	1.5	17
280	A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding. Journal of Virology, 1999, 73, 2921-2929.	1.5	249
281	Influenza A Virus RNA Polymerase Has the Ability To Stutter at the Polyadenylation Site of a Viral RNA Template during RNA Replication. Journal of Virology, 1999, 73, 5240-5243.	1.5	45
282	Transfectant Influenza A Viruses Are Effective Recombinant Immunogens in the Treatment of Experimental Cancer. Virology, 1998, 249, 89-97.	1.1	28
283	Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems. Virology, 1998, 252, 324-330.	1.1	913
284	Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3954-3959.	3.3	81
285	The Role of Interferon in Influenza Virus Tissue Tropism. Journal of Virology, 1998, 72, 8550-8558.	1.5	276
286	Attenuation of Influenza A Virus mRNA Levels by Promoter Mutations. Journal of Virology, 1998, 72, 6283-6290.	1.5	55
287	NS1-Binding Protein (NS1-BP): a Novel Human Protein That Interacts with the Influenza A Virus Nonstructural NS1 Protein Is Relocalized in the Nuclei of Infected Cells. Journal of Virology, 1998, 72, 7170-7180.	1.5	114
288	Development of Novel Influenza Virus Vaccines and Vectors. Journal of Infectious Diseases, 1997, 176, S45-S49.	1.9	38

#	ARTICLE	IF	CITATIONS
289	Negative-strand RNA viruses: genetic engineering and applications.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11354-11358.	3.3	127
290	Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses. Cellular Immunology, 1996, 173, 96-107.	1.4	96
291	Nonconserved Nucleotides at the 3â€² and 5â€² Ends of an Influenza A Virus RNA Play an Important Role in Viral RNA Replication. Virology, 1996, 217, 242-251.	1.1	92
292	NPI-1, the human homolog of SRP-1, Interacts with influenza virus nucleoprotein. Virology, 1995, 206, 116-125.	1.1	158
293	Nuclear Import of Influenza Virus RNA Can Be Mediated by Viral Nucleoprotein and Transport Factors Required for Protein Import. Journal of Biological Chemistry, 1995, 270, 22701-22704.	1.6	205
294	The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. Virus Research, 1995, 37, 37-47.	1.1	56
295	Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Research, 1993, 29, 141-153.	1.1	85
296	Mutational analysis of the influenza virus vRNA promoter. Virus Research, 1993, 28, 99-112.	1.1	78
297	Infectious Influenza Viruses from cDNA-Derived RNA: Reverse Genetics. , 1993, , 107-114.		2
298	Genetic analysis of influenza virus. Current Opinion in Genetics and Development, 1992, 2, 77-81.	1.5	18
299	Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form. Molecular and Biochemical Parasitology, 1992, 51, 49-54.	0.5	82
300	Evolutionary relatedness of the predicted gene product of RNA segment 2 of the Tick-Borne Dhori virus and the PB1 polymerase gene of influenza viruses. Virology, 1991, 182, 1-7.	1.1	34
301	An influenza virus containing nine different RNA segments. Virology, 1991, 185, 291-298.	1.1	144
302	Evolutionary Lineages and Molecular Epidemiology of Influenza A, B, and C Viruses. , 1990, , 119-129.		0
303	Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Virology, 1989, 171, 458-466.	1.1	69
304	Expression of antisense RNA fails to inhibit influenza virus replication. Virus Research, 1989, 14, 141-159.	1.1	17
305	Complementation and analysis of an NP mutant of influenza virus. Virus Research, 1989, 12, 97-111.	1.1	41
306	Amplification, expression, and packaging of a foreign gene by influenza virus. Cell, 1989, 59, 1107-1113.	13.5	469

#	Article	IF	Citations
307	Variation in Influenza Virus Genes. , 1989, , 319-359.		24
308	Influenza B virus evolution: Co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology, 1988, 163, 112-122.	1.1	227
309	Novel method of detecting single base substitutions in RNA molecules by differential melting behavior in solution. Genomics, 1988, 3, 217-223.	1.3	9
310	Correlation of High Evolutionary Rate of Influenza A Viruses in Man with High Mutation Rate Measured in Tissue Culture: A Hypothesis. , 1988, , 23-27.		0
311	Influenza Viruses: Genome Structure, Transcription and Replication of Viral RNA. , 1987, , 299-316.		0
312	Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology, 1987, 160, 336-345.	1.1	193
313	The influenza c virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities. Virology, 1987, 160, 419-425.	1.1	137
314	Germ of an idea. Nature, 1987, 329, 480-480.	13.7	2
315	Epidemiology of influenza C virus in man: Multiple evolutionary lineages and low rate of change. Virology, 1986, 153, 12-21.	1.1	100
316	Detection of single base substitutions in influenza virus RNA molecules by denaturing gradient gel electrophoresis of RNA-RNA or DNA-RNA heteroduplexes. Virology, 1986, 150, 55-64.	1.1	22
317	The influenza C virus NS gene: evidence for a spliced mRNA and a second NS gene product (NS2) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	22
318	RAPID EVOLUTION OF HUMAN INFLUENZA VIRUSES. , 1986, , 53-68.		4
319	Noncumulative sequence changes in the hemagglutinin genes of influenza C virus isolates. Virology, 1985, 146, 221-232.	1.1	113
320	Reassortment Continuum. , 1984, , 144-151.		10
321	Oligonucleotide mapping: evaluation of its sensitivity by computer-simulation. Nucleic Acids Research, 1982, 10, 237-246.	6.5	88
322	Nucleotide sequence of the influenza A/duck/Alberta/60/76 virus NS RNA: Conservation of the NS1/NS2 overlapping gene structure in a divergent influenza virus RNA segment. Virology, 1981, 113, 397-402.	1.1	59
323	An avian tumor virus promoter directs expression of plasmid genes in Escherichia coli. Gene, 1981, 16, 217-225.	1.0	31
324	Antigenic variants of influenza viruses: Marked differences in the frequencies of variants selected with different monoclonal antibodies. Virology, 1980, 102, 458-462.	1.1	51

#	ARTICLE	IF	CITATIONS
325	Sequential passage of influenza virus in embryonated eggs or tissue culture: Emergence of mutants. Virology, 1980, 107, 424-433.	1.1	55
326	The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. Gene, 1980, 8, 315-328.	1.0	323
327	Genetic variation of human influenza viruses. Trends in Biochemical Sciences, 1980, 5, III-V.	3.7	2
328	Evolution of human influenza a viruses in nature: Sequential mutations in the genomes of new H1N1 isolates. Cell, 1979, 18, 73-83.	13.5	104
329	Nonranom association of parental genes in influenza A virus recombinants. Virology, 1979, 95, 269-274.	1.1	99
330	Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature, 1978, 274, 334-339.	13.7	358
331	Molecular weights of RNA segments of influenza A and B viruses. Virology, 1978, 88, 394-399.	1.1	68
332	The Hemagglutinin Gene of Influenza Viruses. Topics in Infectious Diseases, 1978, , 49-57.	0.6	3
333	Common Sequence at the 5â€² Ends of the Segmented RNA Genomes of Influenza A and B Viruses. Journal of Virology, 1978, 25, 312-318.	1.5	19
334	The genes of influenza virus. Cell, 1977, 10, 1-10.	13.5	281
335	Mapping of the influenza virus genome II. Identification of the P1, P2, and P3 genes. Virology, 1977, 76, 114-121.	1.1	72
336	Differences in protein patterns of influenza A viruses. Virology, 1977, 76, 122-128.	1.1	52
337	RNA pattern of â€˜Swineâ€™ influenza virus isolated from man is similar to those of other swine influenza viruses. Nature, 1976, 263, 528-530.	13.7	40
338	Assembly of lipid-containing viruses. Journal of Supramolecular Structure, 1974, 2, 496-511.	2.3	12
339	Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology, 1974, 61, 397-410.	1.1	779
340	Neuraminidase aus Schweinenieren. Reinigung und Eigenschaften. Hoppe-Seyler's Zeitschrift FÃ¼r Physiologische Chemie, 1968, 349, 1169-1178.	1.7	19
341	Genome Plasticity of Influenza Viruses. , 0, , 162-177.		1